Drug profile · INN
orforglipron
orforglipron is an FDA-listed pharmaceutical active ingredient.
Drug details — orforglipron
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 10
- Data quality
- 0.70
Quick answer
orforglipron is an FDA-listed pharmaceutical active ingredient.
Key facts
Approval history
| Authority | Status | Date |
|---|---|---|
| NMPA | clinical trials | — |
Recent coverage
Weight Loss Medications in 2026: GLP-1 Market Shift
Danuglipron Phase 3 Watch After Pfizer’s Phase 2b Obesity Win
Pfizer said its oral GLP-1 danuglipron met the primary endpoint in a Phase 2b obesity trial, showing a statistically significant change in body weight from baseline. The result strengthens the case for Pfizer's oral GLP-1 strategy and sets up investor and BD scrutiny around Phase 3 design, safety, and differentiation.
Pfizer's Danuglipron Hits Phase 2b Obesity Endpoint
Pfizer said danuglipron, its oral GLP-1 receptor agonist, met the primary endpoint in a Phase 2b obesity trial with statistically significant weight loss versus baseline. The result strengthens the case for Danuglipron Phase 3 planning and gives BD and investor teams a fresh benchmark against other oral GLP-1 programs.
Pipeline programs
Frequently asked questions
What is orforglipron?
orforglipron is an FDA-listed pharmaceutical active ingredient.